Suad Nsouli
Family · Washington, DCNPI 1851800502
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 180 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AstraZeneca at 47.7% of the total. Among family clinicians in DC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 180 payments — averaging $35.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$3K
- Sanofi$1K
- Amgen$459
- Regeneron Healthcare Solutions, Inc.$251
- Pfizer$227
- GSK$222
- plus $1K from 16 others
What the payments were for
- Consulting fees$240%
- Food & beverage$6,38899%
- Education$210%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 70 | $3,070 |
| Sanofi | 24 | $1,028 |
| Amgen | 13 | $459 |
| Regeneron Healthcare Solutions, Inc. | 10 | $251 |
| Pfizer | 5 | $227 |
| GSK | 9 | $222 |
| Biocryst US Sales Co., LLC | 6 | $160 |
| Genentech USA, Inc. | 6 | $129 |
| Kaleo, Inc. | 5 | $129 |
| CSL Behring | 4 | $116 |
| Novartis | 4 | $107 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $106 |
| ARS Pharmaceuticals Operations, Inc. | 4 | $106 |
| Optinose US, Inc. | 4 | $78 |
| Hikma Pharmaceuticals USA | 3 | $66 |
| Pharming Healthcare, Inc. | 2 | $44 |
| Dermavant Sciences, Inc. | 1 | $27 |
| Ionis Pharmaceuticals, Inc. | 1 | $25 |
| ADMA Biomanufacturing LLC | 2 | $24 |
| Phadia US Inc. | 1 | $21 |
| Boehringer Ingelheim | 1 | $20 |
| AbbVie | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,434 in reported general payments places this provider in the 95th percentile of 392 family providers in District of Columbia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Azelastine Hcl | 15 | $880 |
| Montelukast Sodium | 12 | $142 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $136 |
Paid to pharmacies, not to this prescriber.
Other family in Washington
- Amy StewartWashington$489K
- Kara CouchWashington$144K
- Laura XandersWashington$109K
- Laura MackeWashington$39K
- Cassandra ThompsonWashington$11K
- Sharmin DiazWashington$9K
- Emily BertrandWashington$8K
- Ana Carrion-GelabertWashington$7K
- Chanda CopelandWashington$7K
- Mitchell WhartonWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.